Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting

Featuring an interview with Prof Constantine Tam, including the following topics: Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00) Considerations for the administration of first-line venetoclax-based regimens (3:24) Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01) Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38) Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07) Up-front treatment selection for patients with del(17p) CLL (24:01) Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20) Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00) Perspectives on future roles of novel therapies and treatment strategies (43:11) CME information and select publications